Drug intelligence / Profile preview

OP-01

Development stage: Preclinical
Lead developer: Eledon Pharmaceuticals

Overview

OP-01 is a drug candidate developed by Otic Pharma, an Israeli company focused on ear, nose, and throat (ENT) disorders. It is being developed for the treatment of acute otitis externa. Otic Pharma's development programs, including OP-01, were integrated into Tokai Pharmaceuticals' pipeline following a reverse merger, after which Tokai Pharmaceuticals changed its name to Novus Therapeutics. The merger provided capital to accelerate the development of OP-01 and other candidates.

Beyond the preview

Go deeper on OP-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OP-01.

Explore the full profile